C10orf113 Activators
C10orf113 (nebulette) is a cardiac-specific actin-binding protein that plays a key role in the structure and function of the sarcomere, the fundamental contractile unit of cardiac muscle. Compounds that elevate intracellular cAMP or cGMP levels indirectly participate in the activation of C10orf113 through the activation of protein kinases such as PKA and PKG. These kinases can phosphorylate proteins within the sarcomere, potentially enhancing the stability and function of C10orf113 in organizing the actin cytoskeleton. The biochemical cascade initiated by beta-adrenergic receptor agonists, for instance, leads to increased cAMP and subsequent PKA activation, which is known to play a crucial role in cardiac muscle contraction. This sequence of events is also supported by agents that inhibit phosphodiesterases, preventing the breakdown of cyclic nucleotides and thus sustaining the activity of kinases that could positively influence C10orf113's role in cardiomyocytes.
In addition to the cyclic nucleotide-mediated pathways, C10orf113's activity in cardiac tissue may also be enhanced by signaling molecules that modulate calcium dynamics and cellular energy balance. The inhibition of the Na+/K+ ATPase by specific cardiac glycosides leads to an increase in intracellular calcium concentration, which activates calcium/calmodulin-dependent protein kinases. These kinases could potentially alter the phosphorylation state of proteins associated with C10orf113, thereby modulating its interaction with actin and influencing cardiac contractility. Furthermore, metabolic regulators that activate AMP-activated protein kinase (AMPK) indirectly affect C10orf113 by altering the energy state of the cardiomyocyte, which is closely linked to muscle contraction and sarcomere integrity. Similarly, the role of sirtuins in mitochondrial function and their reliance on substrates such as NAD+ may have downstream effects on the structural proteins within the sarcomere, including C10orf113, by optimizing the energy supply required for sustained muscle contraction.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-specific inhibitor of phosphodiesterases, leading to increased levels of cAMP and cGMP, which can activate PKA and PKG respectively. This activation could in turn potentiate the actin-modulating activity of C10orf113. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is an activator of protein kinase C (PKC), which can phosphorylate substrates involved in cardiomyocyte function, potentially modulating the actin cytoskeleton and thereby affecting the function of C10orf113. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a synthetic beta-adrenergic receptor agonist which increases intracellular cAMP, leading to PKA activation, potentially enhancing C10orf113 interaction with the actin cytoskeleton in cardiac muscle cells. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine activates beta-adrenergic receptors, increasing cAMP and activating PKA, which could indirectly increase the activity of C10orf113 by phosphorylation of associated regulatory proteins in cardiomyocytes. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AICAR activates AMPK, which is involved in cellular energy homeostasis. AMPK activation could have downstream effects on cardiac muscle contraction and indirectly increase the functional role of C10orf113 within the sarcomere. | ||||||
NAD+, Free Acid | 53-84-9 | sc-208084B sc-208084 sc-208084A sc-208084C sc-208084D sc-208084E sc-208084F | 1 g 5 g 10 g 25 g 100 g 1 kg 5 kg | $57.00 $191.00 $302.00 $450.00 $1800.00 $3570.00 $10710.00 | 4 | |
NAD+ serves as a substrate for sirtuins which regulate cellular processes including mitochondrial function. Enhanced mitochondrial function can affect cardiomyocyte energy status, potentially influencing C10orf113 activity. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
A cAMP analog that activates PKA, leading to changes in cardiomyocyte contractility and potentially increasing the functional activity of C10orf113 by affecting its interaction with the actin cytoskeleton. | ||||||
Ouabain-d3 (Major) | sc-478417 | 1 mg | $516.00 | |||
Ouabain inhibits the Na+/K+ ATPase, leading to increased intracellular calcium levels in cardiomyocytes, which can activate calcium/calmodulin-dependent kinase II (CaMKII) and potentially influence the function of C10orf113. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits phosphodiesterase 5, leading to increased cGMP levels which activate PKG, potentially influencing the cardiomyocyte contractile apparatus and the activity of C10orf113. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram inhibits phosphodiesterase 4, leading to increased cAMP levels, which can activate PKA and potentially result in enhanced C10orf113 activity by affecting its role in cardiomyocyte contraction. | ||||||